Virtu KCG Holdings’s Puma Biotechnology PBYI Stock Holding History

Virtu KCG Holdings’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-15,066	Closed	-$560K	–	3333
2017 Q1	$560K	Buy	+15,066	New	+$550K	0.02%	1255
2016 Q4	–	Sell	-14,937	Closed	-$1M	–	3689
2016 Q3	$1M	Buy	+14,937	New	+$755K	0.02%	702
2016 Q2	–	Sell	-18,240	Closed	-$536K	–	3235
2016 Q1	$536K	Buy	+18,240	New	+$824K	0.02%	1122
2015 Q4	–	Sell	-4,609	Closed	-$347K	–	3826
2015 Q3	$347K	Buy	4,609 +175	+4%	+$16.6K	0.01%	1913
2015 Q2	$518K	Buy	+4,434	New	+$803K	0.01%	1462
2015 Q1	–	Sell	-1,341	Closed	-$254K	–	3684
2014 Q4	$254K	Sell	1,341 -864	-39%	-$192K	﹤0.01%	2565
2014 Q3	$526K	Sell	2,205 -4,840	-69%	-$994K	0.01%	1645
2014 Q2	$465K	Sell	7,045 -668	-9%	-$47.5K	0.01%	2024
2014 Q1	$803K	Buy	+7,713	New	+$907K	0.01%	1451

Other funds holding PBYI

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Virtu KCG Holdings's PBYI Position: Q2 2017 in Review

Virtu KCG Holdings sold out of Puma Biotechnology (PBYI) in Q2 2017, closing a stake of 15,066 shares — an estimated $560K sold.

Virtu KCG Holdings first reported a position in PBYI in Q1 2014 and held it in 9 quarters. The position peaked at $1M in Q3 2016. 154 funds tracked by Wall St. Rank hold PBYI as of Q2 2017.

Virtu KCG Holdings reported no remaining Puma Biotechnology position as of Q2 2017 after selling out during the quarter.
Virtu KCG Holdings sold 15,066 Puma Biotechnology shares in Q2 2017, an estimated $560K.
Virtu KCG Holdings first reported a position in Puma Biotechnology in Q1 2014 and held it in 9 quarters.
Virtu KCG Holdings's Puma Biotechnology position peaked at $1M in Q3 2016.
154 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.